Posted by Michael Wonder on 31 Oct 2025
Schedule of Pharmaceutical Benefits - 1 November 2025
1 November 2025 - The November 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The November issue of the Schedule includes has a few new/revised listings of note:
- Brentuximab vedotin (Adcetris) - new indication
- Brexpiprazole (Rexulti) - new strength
- Daratumumab (Darzalex)/Daratumumab with hyaluronidase (human, recombinant) (Darzalex SC) - new indication
- Durvalumab (Imfinzi) - new indication
- Elafibranor (Iqirvo) - new medicine
- Empagliflozin (Jardiance) - new indication
- Ethinyloestradiol with etonogestrel (NuvaRing) - new combination product
- Iptacopan hydrochloride (Fabhalta) - new medicine
- Tremelimumab (Imjudo) - new medicine
